This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 30, 2012 /PRNewswire/ -- Aequus BioPharma, Inc. ("Aequus"), a majority owned subsidiary of Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), announced today that its GlycoPolymer technology proof of concept studies, featuring recent data with their AQB-101 drug candidate, was selected for an oral presentation at the 9th International Symposium for Polymer Therapeutics meeting. The meeting will be held on
May 28-30, 2012, at the Centro de Investigacion Principe Felipe in
Stewart D. Chipman, Ph.D., the Chief Scientific Officer and President of Aequus, is scheduled to present the data on
Wednesday, May 30, 2012, during the "New Technologies and Novel Therapeutic Targets" session that will be held from 8.30 to 13.00 CET. The presentation is entitled, "AQB-101, A novel glycoprotein with G-CSF activity and a recombinantly ligated amino acid sequence, demonstrates plasma pharmacokinetics comparable to PEG-G-CSF."
Dr. Chipman stated, "The data in this presentation demonstrates thepotential utility of Aequus' proprietary GlycoPolymer technology for extending the plasma half-life of therapeutically useful proteins and peptides that possess limited efficacy due to poor intrinsic pharmacokinetic properties. Aequus believes that application of its straightforward modular GlycoPolymer technology approach, which utilizes industry standard methods and techniques, to biologically active proteins and peptides will facilitate the development of therapeutic protein-based drugs that require less frequent dosing and offer improved patient convenience."
"Aequus' presentation will describe how the company has created a novel hG-CSF-based therapeutic protein candidate, AQB-101, by using the GlycoPolymer technology approach. The AQB-101 glycoprotein possesses a plasma half-life that is comparable to pegylated hG-CSF (Neulasta®), and significantly prolonged compared to hG-CSF (Neupogen®). Aequus believes the AQB-101 glycoprotein could be a suitable candidate for further development as a human therapeutic agent in the market currently dominated by Neulasta®," Dr. Chipman concluded.